Cover Image
市場調查報告書

生物標記的全球市場預測 2017-2027年:生物標記服務,生物標記診斷,生物標記藥物研發,基因學,蛋白質體學,生物資訊學

Global Biomarkers Market Forecast 2017-2027: Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases

出版商 Visiongain Ltd 商品編碼 206674
出版日期 內容資訊 英文 206 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物標記的全球市場預測 2017-2027年:生物標記服務,生物標記診斷,生物標記藥物研發,基因學,蛋白質體學,生物資訊學 Global Biomarkers Market Forecast 2017-2027: Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases
出版日期: 2017年10月18日 內容資訊: 英文 206 Pages
簡介

全球生物標記市場規模預計在預測期間的前半部分將以9.1%的年複合成長率 (CAGR) 擴大。2016年該市場的最大部門為生物標誌物藥物發明,佔全球生物標記市場49.3%。

本報告提供全球生物標記市場相關調查,彙整市場概要,部門,領域,適應症,及各地區的市場收益預測,定性分析 (SWOT·STEP) 、及主要企業簡介等資訊。

第1章 調查概要

第2章 生物標記的簡介

  • 生物標記定義
    • 生物標記的簡歷
    • 生物標記的重要性
  • 生物標記的藥物研發及檢驗
  • 生物標記的利用
    • 醫藥品有效性的評估
    • 醫藥品安全性的評估
    • 搭配診斷
    • 生物標記在治療上的重要性
    • 成像生物標記物
  • 生物標記及個人化醫療
  • 生物標記藥物研發
    • 基因學
    • 蛋白質體學
    • 代謝體學

第3章 全球生物標記市場

  • 全球生物標記市場
  • 全球生物標記市場:整體收益的預測
  • 全球生物標記藥物研發的子市場
  • 全球生物標記診斷的子市場
  • 全球生物標記服務的子市場
  • 全球生物標記市場:整體收益預測,各領域
  • 主要生物標記領域的成長

第4章 生物標記藥物研發·開發主要適應病症症

  • 全球生物標記市場:各適應症
    • 生物標記的級
    • 藥效學生物標記
  • 全球生物標記市場:各適應症的收益預測
  • 全球生物標記市場預測:各適應症
  • 癌症生物標記市場
  • 心臟病生物標記子市場
  • CNS (中樞神經系統) 疾病生物標記子市場
  • 自體免疫疾病生物標記子市場
  • 主要生物標記適應症的成長

第5章 主要國家的生物標記市場

  • 全球生物標記市場:各地區分析
  • 全球生物標記市場:各地區預測
  • 美國的生物標記市場
  • EU5個國家的生物標記市場
  • 日本的生物標記市場
  • 中國的生物標記市場
  • 印度的生物標記市場
  • 俄羅斯的生物標記市場
  • 巴西的生物標記市場
  • 其他 (RoW)的生物標記市場

第6章 生物標記產業趨勢

  • 生物標記市場優勢和弱點
  • 生物標記市場機會和威脅
  • 全球生物標記市場:STEP分析
  • 社會要素
  • 技術性要素
  • 經濟要素
  • 政治要素
  • 開發中的生物標記課題
  • 混合藥·診斷的發展
  • 微型核糖核酸生物標記
  • 大型製藥企業和生物標記

第7章 生物標記市場主要企業

  • 生物標記服務供應商
  • 生物標記技術供應商
  • 生物標記診斷開發者

第8章 結論

  • 全球生物標記市場的狀況
  • 全球生物標記市場上成長
  • 藥物研發·開發上生物標記的利用
  • 新的診斷需求

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0248

The global biomarkers market is expected to grow at a CAGR of 9.1% in the first half of the forecast period. In 2016, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 49.3% of the global biomarkers market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 206-page report you will receive 66 tables and 59 figures- all unavailable elsewhere.

The 206-page report provides clear detailed insight into the global biomarkers market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Biomarkers Market forecasts from 2017-2027
  • This report also breaks down the revenue forecast for the global biomarkers market by Sector:
    • Biomarker Services
    • Biomarker Diagnostics
    • Biomarker Discovery
  • This report also breaks down the revenue forecast for the global biomarkers market by Discipline:
    • Genomics
    • Proteomics
    • Bioinformatics
    • Other
  • This report also breaks down the revenue forecast for the global biomarkers market by Therapeutic Indication:
    • Cancer
    • Cardiovascular Diseases
    • CNS,
    • Autoimmune Diseases
    • Other
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • US
    • EU5 (further segmented into France, Germany, the UK, Spain and Italy)
    • Japan
    • China
    • India
    • Russia
    • Brazil
    • RoW

image1

  • Our study gives qualitative analysis of the biomarkers market. It includes a SWOT and STEP Analysis.
  • Our study discusses the selected leading companies that are the major players in the biomarkers industry. These companies are biomarker service providers, biomarker technology providers and biomarker diagnostic developers:
    • Quintiles IMS Holdings Inc
    • Laboratory Corporation of America Holdings
    • Parexel
    • Charles River Laboratories
    • ICON plc
    • WuXi PharmaTec
    • Caprion Proteomics
    • Proteome Sciences
    • Pacific Biomarkers
    • Oxford Gene Technology (OGT)
    • Worldwide Clinical Trials (WWC)
    • Agilent
    • AB SCIEX
    • QIAGEN
    • Axela Inc
    • Thermo Fisher Scientific
    • Quest Diagnostics
    • Myriad Genetics
    • Genomic Health
    • Critical Diagnostics
    • Epigenomics
    • MDxHealth (formerly OncoMethylome)
  • Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs:
    • Pfizer
    • Novartis
    • Roche Diagnostics
    • Ventana Medical Systems
    • Merck & Co.
    • Sanofi
    • GSK
    • Abbott Laboratories
    • AstraZeneca

Visiongain's study is intended for anyone requiring commercial analyses for the global biomarkers market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Biomarkers: World Market Overview
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods
  • 1.4 Market Definition, 2016

2. An Introduction to Biomarkers

  • 2.1 Definition of a Biomarker
    • 2.1.1 A Brief History of Biomarkers
    • 2.1.2 The Importance of Biomarkers
  • 2.2 Biomarker Discovery and Validation
  • 2.3 Uses of Biomarkers
    • 2.3.1 Assessing Drug Efficacy
    • 2.3.2 Assessing Drug Safety
    • 2.3.3 Companion Diagnostics
    • 2.3.3.1 CLIA vs. FDA Approval
    • 2.3.4 Therapeutic Importance of Biomarkers
    • 2.3.5 Imaging Biomarkers
      • 2.3.5.1 Imaging Biomarkers in Clinical Trials
  • 2.4 Biomarkers and Personalised Medicine
  • 2.5 Biomarker Discovery
    • 2.5.1 Genomics
      • 2.5.1.1 Pharmacogenomics
    • 2.5.2 Proteomics
    • 2.5.3 Metabolomics

3. The World Biomarkers Market, 2016-2027

  • 3.1 The World Biomarkers Market, 2016
    • 3.1.1 The World Biomarkers Market by Sector, 2016
    • 3.1.2 The World Biomarkers Market by Discipline, 2016
  • 3.2 The World Biomarkers Market: Overall Revenue Forecast, 2016-2027
    • 3.2.1 Lack of Investment and Reimbursement Issues May Restrain Market
  • 3.3 The World Biomarker Discovery Submarket, 2016
    • 3.3.1 The World Biomarker Discovery Submarket: Revenue Forecast 2016-2027
  • 3.4 The World Biomarker Diagnostics Submarket, 2016
    • 3.4.1 The World Biomarker Diagnostics Submarket: Revenue Forecast, 2017-2027
  • 3.5 The World Biomarker Services Submarket, 2016
    • 3.5.1 The World Biomarker Services Submarket: Revenue Forecast, 2016-2027
  • 3.6 The World Biomarkers Market: Overall Revenue Forecast by Discipline, 2016-2027
    • 3.6.1 The Genomics Submarket: Revenue Forecast, 2016-2027
      • 3.6.1.1 Next Generation Sequencing to Drive Growth
      • 3.6.1.2 Increased Focus on Genomic Research in China
      • 3.6.1.3 Application in Cardiovascular Disease
    • 3.6.2 The Proteomics Submarket: Revenue Forecast, 2016-2027
      • 3.6.2.1 Advances in Detection Technology Will Drive Market
    • 3.6.3 The Bioinformatics Submarket: Revenue Forecast, 2016-2027
      • 3.6.3.1 Market to Gather Pace with New Tools and Software in Pipeline
  • 3.7 Growth in Key Biomarker Disciplines, 2016-2027

4. Leading Indications for Biomarker Discovery and Development, 2016-2027

  • 4.1 The World Biomarkers Market by Indication, 2016
    • 4.1.1 Class of biomarkers
    • 4.1.2 Pharmacodynamic Biomarkers
  • 4.2 The World Biomarkers Market: Overall Revenue Forecast by Indication, 2016-2027
  • 4.3 Cancer Biomarker Market
    • 4.3.1 A Brief History of Cancer Biomarker Research
    • 4.3.2 The Current State of Cancer Biomarker Research
    • 4.3.3 Companion Diagnostics for Cancer
    • 4.3.4 Initiatives in Cancer Biomarker Research
      • 4.3.4.1 Cancer Genome Atlas
      • 4.3.4.2 The Early Detection Research Network
    • 4.3.5 Many Cancer Diagnostics Are Reaching the Market
    • 4.3.6 Opportunities and Challenges for Cancer Biomarkers
      • 4.3.6.1 Prostate Cancer: The Search for Urine Biomarkers
      • 4.3.6.2 Lung Cancer: High Biomarker Owing to Disease Prevalence
    • 4.3.7 Cancer Biomarker Submarket: Revenue Forecast, 2016-2027
  • 4.4 Cardiovascular Disease Biomarker Submarket 2016
    • 4.4.1 A Brief History of Cardiovascular Biomarker Research
    • 4.4.2 The Current State of Cardiovascular Disease Biomarker Research
    • 4.4.3 Cardiovascular Disease Diagnostics
      • 4.4.3.1 Roche Troponin Test Approved by FDA
    • 4.4.4 Collaborations in Cardiac Biomarker Research
      • 4.4.4.1 Bayer Health Extends Collaboration with Broad Institute and Harvard
      • 4.4.4.2 Singulex Inc Collaboration with University of Manchester
    • 4.4.5 The Future of Cardiovascular Biomarker Research
    • 4.4.6 Cardiovascular Disease Biomarker Submarket: Revenue Forecast, 2016-2027
  • 4.5 CNS Diseases Biomarker Submarket, 2016
    • 4.5.1 The Current State of CNS Disease Biomarker Research
    • 4.5.2 Initiatives in CNS Disease Biomarker Research
    • 4.5.3 Biomarker-Based Diagnostics for CNS Diseases
      • 4.5.3.1 ADtect (DiaGenic)
      • 4.5.3.2 Pittsburgh Compound B (PIB) (GE Healthcare)
      • 4.5.3.3 Florbetapir F18 (18F-AV-45) (Eli Lilly)
      • 4.5.3.4 Flutemetamol (GE Healthcare)
      • 4.5.3.5 Florbetaben (Piramal Imaging)
    • 4.5.4 CSF Biomarkers
    • 4.5.5 Alzheimer's Disease: Beyond Amyloid Beta
      • 4.5.5.1 New Criteria and Guidelines to Diagnose Alzheimer's Disease
    • 4.5.6 Multiple Sclerosis: Search for Disease Biomarker
    • 4.5.7 Parkinson's Disease: Effective Biomarker Yet to be Discovered
      • 4.5.7.1 Fluid-Based Biomarker Discovery
    • 4.5.8 CNS Diseases Biomarker Submarket: Revenue Forecast, 2016-2027
  • 4.6 Autoimmune Disease Biomarker Submarket, 2016
    • 4.6.1 Research Initiatives in Biomarker Research for Autoimmune Disease
    • 4.6.2 Marketed Biomarker Diagnostic Tests for Autoimmune Disease
      • 4.6.2.1 Ventra DA - Myraid Genetics
      • 4.6.2.2 NavigAID SSc - Protagen AG
      • 4.6.2.3 Autoimmune Thyroid Disease Tests - Thermo Fischer
    • 4.6.3 Increasing consolidation within the market
      • 4.6.3.1 Merck, Pfizer and Broad Institute Collaborate on biomarkers For Autoimmune Disorders
      • 4.6.3.2 Protagen AG and Qiagen on Protein Based Companion Diagnostics
    • 4.6.4 Autoimmune Diseases Biomarker Submarket: Revenue Forecast, 2016-2027
  • 4.7 Growth in Key Biomarker Indications, 2016-2027

5. Leading National Biomarker Markets, 2017-2027

  • 5.1 The World Biomarkers Market: Regional Breakdown, 2016
  • 5.2 The World Biomarkers Market: Regional Forecast, 2016-2027
  • 5.3 US Biomarkers Market, 2016
    • 5.3.1 FDA - New Draft Guidance on Companion Diagnostics
    • 5.3.2 FDA major shift in regulation of laboratory developed tests
    • 5.3.3 The US Biomarker Market: Revenue Forecast, 2016-2027
  • 5.4 EU5 Biomarker Markets, 2016
    • 5.4.1 EMA - New Draft Guidance on Companion Diagnostics
    • 5.4.2 EMA - New Draft Guidance on Alzheimer's Treatment
    • 5.4.3 EU5 Biomarker Markets: Revenue Forecasts, 2016-2027
    • 5.4.4 Germany Biomarker Market, 2016
      • 5.4.4.1 Government initiatives: CancerMark Project
      • 5.4.4.2 Germany: Biomarker Market Revenue Forecast, 2017-2027
    • 5.4.5 France Biomarker Market, 2016
      • 5.4.5.1 French Government Funds $17m Cancer Biomarker Effort
      • 5.4.5.2 Immunid Received Funding for Companion Diagnostic for Skin Cancer
      • 5.4.5.3 France: Biomarker Market Revenue Forecast, 2016-2027
    • 5.4.6 UK Biomarker Market, 2016
      • 5.4.6.1 Current stage of biomarker research in the UK
      • 5.4.6.2 100,000 Genomes Project
      • 5.4.6.3 £10 Million investment in Precision Panc project
      • 5.4.6.4 The UK Biomarker Market: Revenue Forecast, 2017-2027
    • 5.4.7 Spain Biomarker Market, 2016
      • 5.4.7.1 Spain: Biomarker Market Revenue Forecast, 2016-2027
    • 5.4.8 Italy Biomarker Market, 2016
      • 5.4.8.1 Italian Government Initiatives on Genomics
      • 5.4.8.2 Italy: Biomarker Market Revenue Forecast, 2017-2027
  • 5.5 Japan Biomarker Market, 2016
    • 5.5.1 PMDA - Guidance on Companion Diagnostics
    • 5.5.2 Japan: Biomarker Market Revenue Forecast, 2017-2027
  • 5.6 China Biomarker Market, 2016
    • 5.6.1 Expanding Economy Driving Biotechnology in China
    • 5.6.2 Companies Entering the Chinese Market
    • 5.6.3 China: Biomarker Market Revenue Forecast, 2017-2027
  • 5.7 India Biomarker Market, 2016
    • 5.7.1 GenomeAsia 100K
    • 5.7.2 New cancer institute funded by Indian Government
    • 5.7.3 India: Biomarker Market Revenue Forecast, 2017-2027
  • 5.8 Russia Biomarker Market, 2016
    • 5.8.1 Russia: Biomarker Market Revenue Forecast, 2017-2027
  • 5.9 Brazil Biomarker Market, 2016
    • 5.9.1 Brazil: Biomarker Market Revenue Forecast, 2017-2027
  • 5.10 RoW Biomarker Market, 2016

6. Biomarker Industry Trends, 2017-2027

  • 6.1 Strengths and Weaknesses of the Biomarkers Market, 2016
  • 6.2 Opportunities and Threats in the Biomarkers Market, 2017-2027
  • 6.3 STEP Analysis of The World Biomarkers Market
  • 6.4 Social Factors
    • 6.4.1 Patient Stratification: Striving Towards Personalised Medicine
    • 6.4.2 Biomarker Hype May Not Always Lead to New Discoveries
    • 6.4.3 Growing Emphasis on Oncology for Companies
  • 6.5 Technological Factors
    • 6.5.1 Decreasing Size, Increasing Sensitivity
      • 6.5.1.1 ABT Molecular Imaging
    • 6.5.2 The Need for More-Efficient Data Storage
  • 6.6 Economic Factors
    • 6.6.1 Biomarkers: Cutting the Cost of Drug Development
      • 6.6.1.1 Toxicity Biomarkers: Aiming to Reduce Clinical Drug Failures
    • 6.6.2 High Cost of Technology: Potential Barrier to Entry for Start-Ups
    • 6.6.3 Outsourcing Biomarker Discovery and Development
  • 6.7 Political Factors
    • 6.7.1 Public-Private Partnerships: Collaborative Efforts Aid Biomarker Discovery
    • 6.7.2 Improving Regulatory Guidelines to Speed Development
    • 6.7.3 Concerns Over Biomarker Patenting Hits Innovation
  • 6.8 Challenges in Developing Biomarkers
  • 6.9 Combining Drug and Diagnostic Development
  • 6.10 MicroRNA Biomarkers: A Prospective Target?
  • 6.11 Big Pharma and Biomarkers
    • 6.11.1 Pfizer
    • 6.11.2 Novartis
    • 6.11.3 Merck & Co.
    • 6.11.4 Sanofi
    • 6.11.5 Roche
      • 6.11.5.1 Roche Diagnostics
      • 6.11.5.2 Ventana Medical Systems
    • 6.11.6 GSK
    • 6.11.7 AstraZeneca
    • 6.11.8 Abbott Laboratories

7. Leading Companies in the Biomarkers Market, 2016

  • 7.1 Biomarker Service Providers
    • 7.1.1 Global CROs and Biomarkers
      • 7.1.1.1 Not All Global CROs Are Investing in Biomarkers
    • 7.1.2 Quintiles IMS Holdings Inc
      • 7.1.2.1 Quintiles and IMS Health Merger
    • 7.1.3 Laboratory Corporation of America Holdings
      • 7.1.3.1 LabCorp Diagnostics
      • 7.1.3.2 Covance Drug development
      • 7.1.3.3 Companion and Complimentary Diagnostics Launched for Cancer in 2016
    • 7.1.4 Parexel
    • 7.1.5 Charles River Laboratories
    • 7.1.6 ICON plc
    • 7.1.7 WuXi PharmaTec
    • 7.1.8 Caprion Proteomics
    • 7.1.9 Proteome Sciences
    • 7.1.10 Pacific Biomarkers
    • 7.1.11 Oxford Gene Technology
    • 7.1.12 Worldwide Clinical Trials
  • 7.2 Biomarker Technology Providers
    • 7.2.1 Agilent
      • 7.2.1.1 Diagnostics and Biomarker Assays
      • 7.2.1.2 Growing Asian Markets: Focus on South Korea
    • 7.2.2 AB SCIEX
      • 7.2.2.1 Partnership with Illumina, OneOmics project
    • 7.2.3 QIAGEN
    • 7.2.4 Axela
    • 7.2.5 Thermo Fisher Scientific
      • 7.2.5.1 Strategic Acquisitions
      • 7.2.5.2 Research Collaborations
      • 7.2.5.3 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Centre
  • 7.3 Biomarker Diagnostic Developers
    • 7.3.1 Quest Diagnostics
      • 7.3.1.1 Acquisition of Med Fusion and ClearPoint Diagnostics
      • 7.3.1.2 Q2 Solutions, Join Venture Between Quest Diagnostics and Quintiles IMS Holdings Inc
    • 7.3.2 Myriad Genetics
      • 7.3.2.1 Pipeline
      • 7.3.2.2 BRACAnalysis Gains Approval as Companion Diagnostic
      • 7.3.2.3 Strategic Acquisitions
      • 7.3.2.4 Myriad RBM
    • 7.3.3 Genomic Health
      • 7.3.3.1 Collaborations with Epic Sciences and Biocartis
    • 7.3.4 Critical Diagnostics
    • 7.3.5 Epigenomics
      • 7.3.5.1 Diagnostic Product Portfolio
    • 7.3.6 MDxHealth
      • 7.3.6.1 Diagnostic Product Portfolio and Pipeline

8. Conclusions

  • 8.1 State of the World Biomarkers Market in 2016
  • 8.2 Growth in the World Biomarkers Market, 2017-2027
    • 8.2.1 Dominance of Leading Western Markets
  • 8.3 The Use of Biomarkers in Drug Discovery and Development
  • 8.4 Demand for New Diagnostics

Appendices

  • Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Figures

  • Figure 2.1 Definitions of a Biomarker, 2016
  • Figure 2.2 The Biomarker Discovery and Validation Process, 2016
  • Figure 3.1 World Biomarkers Market: Market Shares (%) by Sector, 2016
  • Figure 3.2 World Biomarkers Market: Market Shares (%) by Discipline, 2016
  • Figure 3.3 World Biomarkers Market: Drivers and Restraints, 2016-2027
  • Figure 3.4 World Biomarkers Market: Overall Market Forecast ($bn), 2016-2027
  • Figure 3.5 World Biomarkers Market: Market Shares (%) by Sector, 2021
  • Figure 3.6 World Biomarkers Market: Market Shares (%) by Sector, 2027
  • Figure 3.7 Biomarker Discovery Submarket: Drivers and Restraints, 2017-2027
  • Figure 3.8 Biomarker Discovery Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 3.9 Biomarker Diagnostics Submarket: Revenue Forecast ($bn), 2017-2027
  • Figure 3.10 Biomarker Diagnostics Submarket: Drivers and Restraints, 2017-2027
  • Figure 3.11 Biomarker Services Submarket: Drivers and Restraints, 2016-2027
  • Figure 3.12 Biomarker Services Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 3.13 Genomics Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 3.14 Genomics Submarket: Drivers and Restraints, 2016-2027
  • Figure 3.15 Proteomics Submarket: Drivers and Restraints, 2017-2027
  • Figure 3.16 Proteomics Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 3.17 Bioinformatics Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 3.18 Bioinformatics Submarket: Drivers and Restraints, 2016-2027
  • Figure 3.19 World Biomarkers Market: Market Shares (%) by Discipline, 2021
  • Figure 3.20 World Biomarkers Market: Market Shares (%) by Discipline, 2027
  • Figure 4.1 World Biomarkers Market: Market Share (%) by Indication, 2016
  • Figure 4.2 Pharmacodynamic Biomarkers in Drug Labelling by Indication
  • Figure 4.3 Cancer Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 4.4 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 4.5 CNS Diseases Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 4.6 CNS Diseases Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 4.7 World Biomarkers Market: Market Share (%) by Indication, 2021
  • Figure 4.8 World Biomarkers Market: Market Shares (%) by Indication, 2027
  • Figure 5.1 World Biomarkers Market: Market Shares (%) by Country, 2016
  • Figure 5.2 World Biomarkers Market: Market Shares (%) by Country, 2021
  • Figure 5.3 World Biomarkers Market: Market Shares (%) by Country, 2027
  • Figure 5.4 US Biomarkers Market: Revenue Forecast ($bn), 2017-2027
  • Figure 5.5 Top 5 EU Biomarker Markets: Market Share (%) by Country, 2016
  • Figure 5.6 Top Five EU Biomarker Markets: Revenue Forecasts ($bn), 2017-2027
  • Figure 5.7 Germany: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.8 France: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.9 UK Biomarker Market: Revenue Forecast ($bn), 2017-2027
  • Figure 5.10 Spain: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.11 Italy: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.12 Japan Biomarker Market: Revenue Forecast ($bn), 2017-2027
  • Figure 5.13 China: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.14 India: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.15 Russia: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.16 Brazil: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.17 RoW: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 6.1 US Cancer Deaths by Tumour Type, 2016
  • Figure 6.2 Average Cost of Sequencing the Human Genome ($mn), 2005-2015
  • Figure 7.1 Laboratory Corporation of America: Revenue by Sector ($bn), 2015-2016
  • Figure 7.2 Proteome Sciences: Revenue ($mn), 2015-2016
  • Figure 7.3 Myriad Genetics: Market Shares by Molecular Diagnostic Product (%), 2016
  • Figure 7.4 Genomic Health: Product Revenue ($mn), 2015-2016
  • Figure 7.5 Epigenomics Revenue ($mn), 2016-2017
  • Figure 7.6 MDxHealth: Revenue by Source ($mn), 2015-2016
  • Figure 8.1 World Biomarkers Market: Revenues ($bn) by Sector, 2016, 2021 and 2027
  • Figure 8.2 World Biomarkers Market: Revenues ($bn) by Discipline, 2016, 2021 and 2027
  • Figure 8.3 World Biomarkers Market: Revenues ($bn) by Disease, 2016, 2021 and 2027
  • Figure 8.4 World Biomarkers Market: Revenues ($bn) by Country, 2016, 2021 and 2027

List of Tables

  • Table 2.1 Selected Drugs with Pharmacogenomic Biomarkers Listed on their Labels, 2016
  • Table 2.2 Selected Clinically-Relevant Cancer Biomarkers, 2016
  • Table 2.3 Technologies and Platforms for Biomarker Research, 2016
  • Table 3.1 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Sector, 2016
  • Table 3.2 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Discipline, 2016
  • Table 3.3 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Sector, 2016-2027
  • Table 3.4 World Biomarkers Market: Market Shares (%) by Sector, 2016, 2021, 2027
  • Table 3.5 Biomarker Discovery Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 3.6 Biomarker Diagnostics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 3.7 Biomarker Services Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 3.8 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Discipline, 2016-2027
  • Table 3.9 Genomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 3.10 Selected Producers of Single-Molecule Sequencing Technologies, 2016
  • Table 3.11 Proteomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 3.12 Bioinformatics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 3.13 World Biomarker Market: Market Shares (%) by Discipline, 2016, 2021, 2027
  • Table 4.1 World Biomarkers Market: Market Share (%) by Indication, 2016
  • Table 4.2 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Indication, 2016-2027
  • Table 4.3 Selected Marketed Biomarker-Based Cancer Diagnostics, 2016
  • Table 4.4 Selected ALK Inhibitors in Development for Lung Cancer, 2016
  • Table 4.5 Cancer Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 4.6 Cardiovascular Disease Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 4.7 Research Collaborations in CNS Biomarker Research
  • Table 4.8 CNS Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 4.9 Autoimmune Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 4.10 World Biomarkers Market: Market Share (%) by Indication, 2016, 2021, 2027
  • Table 5.1 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Country, 2016
  • Table 5.2 World Biomarkers Market: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2017-2027
  • Table 5.3 World Biomarkers Market: Market Shares (%) by Country, 2016, 2021, 2027
  • Table 5.4 US Biomarkers Market: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.5 Top 5 EU Biomarker Markets: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2016
  • Table 5.6 Top Five EU Biomarkers Markets: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2017-2027
  • Table 5.7 Germany: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.8 France: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.8 Germany: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.9 UK Biomarker Market: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.10 Spain: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.11 Italy: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.12 Japan: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.13 China: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.14 India: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.15 Russia: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.16 Brazil: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.17 RoW: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 6.1 World Biomarkers Market: Strengths and Weaknesses, 2017-2027
  • Table 6.2 World Biomarkers Market: Opportunities and Threats, 2017-2027
  • Table 6.3 World Biomarkers Market: STEP Analysis, 2017-2027
  • Table 6.4 US Cancer Deaths by Tumour Type, 2016
  • Table 6.5 Selected Cancer Therapies Approved with a Biomarker, 2016
  • Table 6.6 PSTC Biomarkers in Development, 2016
  • Table 6.7 Average Cost of Sequencing the Human Genome: Revenue Forecast ($m, AGR %, CAGR %), 2005-2015
  • Table 6.8 IMI-Funded Biomarker Projects
  • Table 6.9 Drug Discovery Outsourcing: Overall Market and Subsector Forecast ($bn, AGR %, CAGR %), 2016, 2021 & 2027
  • Table 7.1 Laboratory Corporation of America: Revenue by Sector ($bn) 2015-2016
  • Table 7.2 Proteome Sciences: Revenue ($mn), 2015-2016
  • Table 7.3 Myriad Genetics: Biomarker Product Portfolio, 2016
  • Table 7.4 Company Revenue by Sector ($mn), 2016
  • Table 7.5 Myriad Genetics: Diagnostic Pipeline, 2016
  • Table 7.6 Genomic Health: Revenue by Division ($bn), 2015-2016
  • Table 7.7 Epigenomics: Revenue and Market Shares by Sector ($mn), 2015 -2016
  • Table 7.8 MDx Health: Revenue by Source ($mn), 2015-2016
  • Table 7.9 MDxHealth: Pipeline, 2016
  • Table 8.1 World Biomarkers Market: Revenues ($bn, CAGR %, Market Share %) by Sector, 2016, 2021 and 2027
  • Table 8.2 World Biomarkers Market: Revenues ($bn, CAGR %) by Discipline, 2016, 2021 and 2027
  • Table 8.3 World Biomarkers Market: Revenues ($bn, CAGR %) by Disease, 2016, 20121 and 2027
  • Table 8.4 World Biomarkers Market: Revenues ($bn, CAGR %) by Country, 2016, 2021 and 2027

Companies Listed

  • 454 Life Sciences (a subsidiary of Roche)
  • AB SCIEX
  • Abbott Laboratories
  • Abbott Molecular
  • Abcodia
  • ABT Molecular Imaging
  • ACS Biomarker
  • Advanced Cell Diagnostics (ACD)
  • Advion Bioanalytical Labs (part of Quintiles)
  • Affymetrix
  • Agendia
  • Agilent
  • Alacris Theranostics
  • Alere
  • Amarantus BioSciences
  • Amgen
  • Applied Biosystems (part of Life Technologies)
  • Aptiv Solutions
  • Arctic Partners
  • ARIAD Pharmaceuticals
  • Ariana Pharma
  • Arizona State University
  • Arrayit
  • ARUP Laboratories
  • AstraZeneca
  • Athena Diagnostics (a subsidiary of Quest Diagnostics)
  • Atherotech Diagnostics Lab
  • Aushon Biosystems
  • Axela Inc
  • Bayer
  • Belfer Institute for Applied Cancer Science [US]
  • Berkeley HeartLab (a subsidiary of Quest Diagnostics)
  • BG Medicine
  • BGI (formerly Beijing Genomics Institute)
  • Biofortis
  • Biosoft
  • BRAHMS (part of Thermo Fisher Scientific)
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Cancer Research Technology
  • Caprion Proteomics
  • CBC (Comprehensive Biomarker Centre GmbH)
  • Celera (part of Quest Diagnostics)
  • Celgene
  • Cell Signaling Technology
  • Celldex Therapeutics
  • Cephalon (part of Teva)
  • Charles River Laboratories
  • Chronix Biomedical
  • Chugai Pharmaceutical
  • Ciphergen Biosystems
  • Clarient Diagnostic Services
  • Cleveland HeartLab
  • Clinigene International
  • Comprehensive Biomarker Center (formerly Febit)
  • Covance
  • Crelux
  • Critical Diagnostics
  • Critical Path Institute (C-Path) [US]
  • CTI Biotech
  • Daiichi Sankyo
  • Dako (now part of Agilent)
  • Dana-Farber Cancer Institute [US]
  • Danaher
  • DaVita Labs
  • DiaGenic
  • Durin Technologies
  • DxS (now part of QIAGEN)
  • EKO Diagnostic
  • Eli Lilly and Co.
  • Epic Sciences
  • Epigenomics
  • Epistem
  • EQT
  • Evotec
  • Exact Sciences
  • Exiqon
  • Exonhit
  • Ezose Sciences (part of Shionogi)
  • FEI Company
  • Foundation Medicine
  • Fujirebio Diagnostics
  • GE Healthcare
  • Genetic Technologies
  • Geneva Bioinformatics (GeneBio)
  • Genomic Health
  • GenWay Biotech
  • Great Point Partners
  • GSK
  • HD Biosciences
  • Health Diagnostic Laboratory
  • HealthLinx
  • Helicos BioSciences
  • Hewlett-Packard
  • HTG Molecular Diagnostics
  • ICON Plc
  • Illumina
  • ImmunId
  • Insight Genetics
  • Institute of Pathology Heidelberg (IPH)
  • Integrated Diagnostics
  • Ipsen
  • Ipsogen (a subsidiary of QIAGEN)
  • Isogen Life Science
  • Johnson & Johnson (J&J)
  • KU Leuven (University of Leuven)
  • LabCorp
  • Life Technologies
  • LightArray Biotech
  • M2Gen
  • Mayo Clinic [US]
  • Mayo Collaborative Services
  • MDxHealth
  • Medical Research Council [UK]
  • MediMedia Pharma Solutions
  • Memorial Sloan-Kettering Cancer Center [US]
  • Merck & Co.
  • Merck KGaA
  • Metabolon
  • Michael J Fox Foundation
  • Myriad Genetics
  • Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics)
  • National Academy of Sciences (NAS) [US]
  • Nephromics
  • Novartis
  • Novartis Molecular Diagnostics (part of Novartis)
  • NovioGendix
  • Oncoimmune
  • Oncomedics
  • OpGen
  • OPKO Health
  • Orion Genomics
  • Oxford Cancer Biomarkers
  • Oxford Gene Technology
  • Pacific Biomarkers
  • Pacific Biosciences
  • Panomics (now part of Affymetrix)
  • Parexel
  • Patheon
  • Pathwork Diagnostics
  • Personal Genome Diagnostics
  • Pfizer
  • Pierre Fabre
  • PLUS Diagnostics
  • PMDA
  • Power3 Medical Products
  • PPD
  • Predictive Biosciences
  • Prometheus Laboratories
  • ProtagenAG
  • Proteome Sciences
  • QIAGEN
  • QLIDA Diagnostics
  • Quanterix
  • Quanticel Pharmaceuticals
  • Quest Diagnostics
  • Quintiles
  • Quintiles IMS Holdings Inc
  • Randox Laboratories
  • Randox Laboratories
  • Roche
  • SABiosciences (now part of QIAGEN)
  • Sandor Proteomic
  • Sanger Institute
  • Sanofi
  • Santaris Pharma
  • Servier
  • Shionogi
  • Siemens
  • Siemens Healthcare
  • Singulex Inc
  • Sividion Diagnostics
  • SMA Foundation [US]
  • Stemina Biomarker Discovery
  • Sysmex
  • Technology Strategy Board (TSB) [UK]
  • Teva Pharmaceutical Industries
  • Thallion Pharmaceuticals
  • The Biomarkers Consortium
  • Thermo Fisher Sciences
  • Thermo Fisher Scientific
  • Transgene
  • Trans-Hit Biomarkers
  • Tufts Center for the Study of Drug Development
  • Ventana Medical Systems
  • Vertex Pharmaceuticals
  • WaferGen
  • Warnex
  • Worldwide Clinical Trials
  • WuXi AppTec
  • Wuxi Pharmatech
  • Xcovery

List of Organizations Mentioned in the Report

  • American College of Cardiology Foundation (ACCF)
  • American Heart Association (AHA)
  • Association for Molecular Pathology (AMP) [US]
  • British Heart Foundation [UK]
  • Broad Institute [US]
  • Cancer Research UK
  • Centers for Medicare and Medicaid Services (CMS) [US]
  • Chinese State Food and Drug Administration (SFDA)
  • Commonwealth Scientific and Industrial Research Organisation (CSIRO) [Australia]
  • EMA (European Medicines Agency)
  • ETH Zurich
  • European Commission
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Medicines Agency (EMA)
  • European Stroke Research Network for Hypothermia (Euro-HYP)
  • Food and Drug Administration (FDA) [US]
  • Hirosaki University
  • Human Proteome Organisation (HUPO)
  • International Cancer Genome Consortium (ICGC)
  • Les entreprises du médicament (LEEM) [France]
  • Malmö University
  • Massachusetts General Hospital
  • Max Planck Institute for Molecular Genetics [Germany]
  • National Academy of Sciences
  • National Cancer Institute (NCI) [US]
  • National Health Service (NHS) [UK]
  • National Human Genome Research Institute (NHGRI) [US]
  • National Institute for Health and Clinical Excellence (NICE) [UK]
  • National Institute of Allergy and Infectious Diseases (NIAID) [US]
  • National Institute on Aging (NIA) [US]
  • National Jewish Health [US]
  • Newcastle University [UK]
  • NIH (National Institute of Health)
  • Oslo University Hospital
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
  • Predictive Safety Testing Consortium (PSTC) [US]
  • Shanghai Jiao Tong University
  • Stanford University
  • State Food and Drug Administration (SFDA) [China]
  • Technion-Israel Institute of Technology
  • University of Alabama
  • University of Medicine and Dentistry of New Jersey (UMDNJ)
  • University of Oslo
  • University of Turku
  • University of Washington
  • Wellcome Trust Sanger Institute [UK]
  • World Health Organization (WHO)
Back to Top